Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 65 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
EXTRA-PHARMA from Kapellen, company number BE0467149426, closed financial year 2025 with a result of € 97,780 after tax. For that financial year EXTRA-PHARMA recorded a gross margin of € 765,107 and equity of € 559,094. Compared with financial year 2024, the result moved from € 413,070 to € 97,780. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on September 29, 2025.
€ 559,094
▲ 17% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 97,780
▼ 76% vs 2024
Profit after tax over the fiscal year.
€ 159,799
▼ 64% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 540,494.
People and assets in 2025
8.7
▼ 0.5 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 524,774
▼ 1% vs 2024
€ 60,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
€ 2.1 million
▼ 9% vs 2024
€ 194,293 is repaid this year. At this pace the long-term loan is gone in ≈ 10 years.
€ 368,072
Supplier invoices still open on the last day of the fiscal year.
€ 60,177
▲ 8% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 796,528 | € 785,271 | € 896,503 | € 765,107 | ▼ 15% |
| Profit after taxes | € 252,780 | € 180,445 | € 413,070 | € 97,780 | ▼ 76% |
| Equity | € 3,182,375 | € 3,339,502 | € 477,161 | € 559,094 | ▲ 17% |
| Total debts | € 1,852,700 | € 2,902,143 | € 2,952,782 | € 2,504,552 | ▼ 15% |
| Cash | € 304,759 | € 171,804 | € 446,044 | € 159,799 | ▼ 64% |
| Land & buildings | € 1,084,616 | € 2,153,395 | € 1,660,790 | € 1,598,073 | ▼ 4% |
| Retained profit | € 3,163,775 | € 3,320,902 | € 458,561 | € 540,494 | ▲ 18% |
| Dividend | € 0 | € 0 | € 3,250,000 | € 0 | ▼ 100% |
| Bank debt | € 1,103,370 | € 2,357,665 | € 2,250,422 | € 2,056,710 | ▼ 9% |
| Balance sheet total | € 5,035,075 | € 6,241,645 | € 3,429,943 | € 3,063,645 | ▼ 11% |
| Employees (FTE) | 7.9 | 8.8 | 9.2 | 8.7 | ▼ 0.5 |
Key figures of EXTRA-PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2026 has not been filed yet; it was expected before 31 October 2026.
What happened to EXTRA-PHARMA?
What happened at EXTRA-PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 97,780 (▼ 76% vs 2024). Source: NBB ↗
- Cavely BV became a director. NBB
- Verluco NV stepped down as director. NBB
- New establishment in Kapellen. KBO
- Start of the company according to the CBE. KBO
In short
From € 252,780 profit in 2022 to € 97,780 profit in 2025.
Paid € 176,857 in corporate taxes since 2022.
Best year ever: 2024, with € 413,070 profit.
On average € 87,900 of value added per employee in 2025.
Management
The stake of Cavely comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
EXTRA-PHARMABehind EXTRA-PHARMA is Cavely BV. The shares are held by Cavely (100%).
Directors
According to the 2025 annual accounts
Director · represented by Carlijn Van den Eede
since 2024
Director · represented by Luc Roger J Van den Eede
· until 2024
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Antwerpsesteenweg 188
2950 Kapellen
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0467.149.426
- VAT number
- BE 0467.149.426
- Registered office
- Antwerpsesteenweg 188, 2950 Kapellen
- Names & denominations
- EXTRA-PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 26 October 1999
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers